Will Ashworth

Will Ashworth

Expertise: Public and private companies, Portfolio construction

About Will:
Will Ashworth has written about investments full-time since 2008. He loves investing and is passionate about helping others put their money to work. He particularly enjoys creating model portfolios that stand the test of time.

Publications where he’s appeared include InvestorPlace, The Motley Fool Canada, Investopedia, Kiplinger, and several others in both the U.S. and Canada. He lives in Halifax, Nova Scotia.

You can follow Will on LinkedIn. 

Recent Articles

7 Blue-Chip Stocks to Buy Investors Are Overlooking

When it comes to picking blue-chip stocks from the S&P 500, it's not just dividends that matter, and some names are being overlooked.

OrganiGram’s Latest Director Appointment Deserves Closer Scrutiny

OrganiGram recently announced it appointed its first U.S. resident as a director. That’s a good thing if you own OGI stock. Here’s why.  

10 Dividend Stocks Increasing Their Payouts 

When it comes to investing in dividend stocks, companies that significantly increase their payouts are more attractive than those with higher yields.

Despite Market Over-Enthusiasm, Zomedica Is Worth Real Consideration

Zomedica just raised approximately $200 million from a bought deal. Loaded with cash, ZOM stock look ready to move higher.

Nokia Won’t Revisit It’s Reddit-Fueled High Anytime Soon

Nokia has traded in a tight range between $3 and $4, except for a brief period when NOK stock went Reddit crazy. Is $10 a possibility?   

Pass on AMC Entertainment for This Promising Cinema Stock Instead

After AMC Entertainment’s big comedown from its 15 minutes of Reddit fame, AMC stock isn’t even the best bet in cinema stocks. Here's why.

Is It Time to Move on From Star Peak Energy?

Star Peak Energy will soon merge with Stem Inc. Should investors focus their attention away from STPK stock and on to Star Peak Corp II?    

2 Potential Buys to Avoid a 90% Drop in Tesla Stock

Michael Burry of "The Big Short fame" believes Tesla stock could fall 90% in 2021. Here are two options that may provide protection.

BioNano Genomics’ Next Double Won’t Come Easily

Bionano Genomics makes Saphyr, a genome imaging tool. With BNGO stock doubling over the past month, investors should give the company a look.

Don’t Make the Same Mistake With QuantumScape That Others Might

Investors are getting certain stocks mixed up lately. If you bought QuantumScape and QS stock instead of Quantum, you’ve lost a ton of money.